Earnings Report /

Ibn Sina Pharmaceutical Industry Ltd: Q1 FY22 – Earnings increased by c40% YoY driven by c37% sales growth

  • IBNSINA reported BDT 4.5 EPS (NPAT BDT 142mn) in Q1 FY22, implying c40% YoY growth

  • Revenue had 37% YoY growth because of higher sales of drugs to treat COVID symptoms and normalized doctor consultancy.

  • We updated our TP to BDT 370 (c7% higher) as we revised up 2022f revenue by c12% and eps by c8%.

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

Shopnil Paul
Shopnil Paul

Research Associate

IDLC Securities
14 November 2021
Published by